The US Food and Drug Administration has granted approval for Teva’s generic version of Takeda’s Prevacid SoluTab (lansoprazole).

The Israeli pharmaceutical firm has been granted permission to market the drug in the US, and shipment of the medication has already commenced.

Lansoprazole, which belongs to the proton pump inhibitor drug group, is used to treat and prevent stomach and intestinal ulcers by lowering the amount of stomach acid the body prooduces.

Annual sales of the brand product stood at approximately $453m in the US, according to IMS sales data.